RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dumping 20M shares and keeping 10M warrants @$3.18Not ascribing any value to any stage of a trial is not the way market looks at other R&D companies.
I posted earlier an article about how to value R&D programs from preclinical all the way through all the stages.
The NASH might have weaknesses but it also has strength, the drug is safe, they know the dosing, it worked in HIV liver battling with adverse effects of ART, the program is innovative and unique vs other programs which have been failing for years.
The market doesn't get it because of inefficient marketing.